Bausch Health Companies (NYSE:BHC) had its price objective reduced by Morgan Stanley from $34.00 to $32.00 in a research report released on Tuesday, BenzingaRatingsTable reports. They currently have an overweight rating on the stock.
A number of other equities analysts have also commented on the company. HC Wainwright reiterated a buy rating and issued a $60.00 price objective on shares of Bausch Health Companies in a research note on Monday, December 23rd. Goldman Sachs Group started coverage on Bausch Health Companies in a research note on Monday, December 2nd. They issued a neutral rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. upgraded Bausch Health Companies from a neutral rating to an overweight rating and lifted their price objective for the stock from $32.00 to $38.00 in a research note on Thursday, December 12th. Barclays reiterated a buy rating and issued a $33.00 price objective on shares of Bausch Health Companies in a research note on Sunday, January 26th. Finally, Wolfe Research downgraded Bausch Health Companies from an outperform rating to a peer perform rating in a research report on Wednesday, January 29th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $34.06.
Bausch Health Companies stock opened at $27.74 on Tuesday. The company has a debt-to-equity ratio of 9.17, a quick ratio of 0.86 and a current ratio of 1.15. The business’s 50-day simple moving average is $28.82 and its 200-day simple moving average is $25.51. The firm has a market capitalization of $9.67 billion, a PE ratio of 6.38, a PEG ratio of 0.57 and a beta of 1.02. Bausch Health Companies has a 52 week low of $18.72 and a 52 week high of $31.97.
A number of hedge funds have recently added to or reduced their stakes in BHC. Renaissance Technologies LLC boosted its holdings in Bausch Health Companies by 146.8% during the fourth quarter. Renaissance Technologies LLC now owns 12,491,799 shares of the company’s stock valued at $373,769,000 after purchasing an additional 7,429,396 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in Bausch Health Companies by 4.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 2,379,185 shares of the company’s stock valued at $71,185,000 after purchasing an additional 96,210 shares in the last quarter. Ardevora Asset Management LLP boosted its holdings in Bausch Health Companies by 7.1% during the third quarter. Ardevora Asset Management LLP now owns 1,916,320 shares of the company’s stock valued at $41,872,000 after purchasing an additional 127,800 shares in the last quarter. FMR LLC boosted its holdings in Bausch Health Companies by 410.9% during the fourth quarter. FMR LLC now owns 1,909,946 shares of the company’s stock valued at $57,171,000 after purchasing an additional 1,536,120 shares in the last quarter. Finally, CIBC World Markets Inc. boosted its holdings in Bausch Health Companies by 1.7% during the fourth quarter. CIBC World Markets Inc. now owns 1,906,462 shares of the company’s stock valued at $57,041,000 after purchasing an additional 32,386 shares in the last quarter. 57.38% of the stock is currently owned by institutional investors and hedge funds.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Recommended Story: How to Invest in an Index Fund
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.